FIELD: medicine, pediatrics, otolaryngology, endocrinology.
SUBSTANCE: the present innovation deals with preventing acute respiratory diseases of the upper respiratory tract in children at insulin-dependent diabetes mellitus during the period of compensation and subcompensation. Before vaccination it is necessary to determine the concentration of antibodies to total antigens of "Pneumo 23" vaccine in blood serum and detect the coefficient of balance capacity (Cbc) in saliva. At the titer of total antibodies to total antigens of "Pneumo 23" vaccine being below 30 CU/ml and Cbc being above 2.1 one should be fulfill vaccination due to single introduction of "Pneumo 23" vaccine into area of deltoid muscle at the dosage of 0.5 ml simultaneously with immunomodulator "IRS-19" introduced per a dose for each nasal meatus twice daily for 14 d including the day of vaccination. The innovation suggested provides the stable maintenance of a stable high titer of antibodies to antigens of "Pneumo 23" vaccine, higher lysozyme activity and secretory immunoglobulin A and prevents acute respiratory diseases in postvaccinal period.
EFFECT: higher accuracy and efficiency of prophylaxis.
3 ex, 1 tbl
